Xenon at wells fargo healthcare conference: azetukalner launch nears

Xenon Pharmaceuticals made a significant move at the Wells Fargo 21st Annual Healthcare Conference, shifting focus towards its first drug launch, azetukalner, alongside programs for depression and pain. The company is aiming to become a fully integrated commercial biopharma by late 2027. Management highlighted an azetukalner NDA expected this month following the completion of the X-TOLE2 Phase III study.

Xenon plans a specialty distribution model and a sales force of about 75 representatives to navigate pharmacy and prior authorization barriers. Azetukalner, a novel Kv7 potassium channel modulator, is expected to have a flat pricing structure due to its potential for broader adoption. The company expects an annual price north of $15,000 to $18,000, similar to branded epilepsy drugs XCOPRI and BRIVIACT.

Xenon plans to target physician adoption, estimating about 7,000 to 8,000 prescribers, including epileptologists and general neurologists. The specialty distribution model aims to improve patient data collection and reduce abandonment. Management anticipates azetukalner to outperform traditional epilepsy launches but not grow as rapidly as oncology or rare disease drugs.